Table 4.

Associations of FGF21 levels with incident rapid kidney function decline over follow-up period

Biomarkers	n		Model 1a		Model 2b		Model 3c
	Total	Event	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
ln-transformed FGF21 levels	5098	886	1.25 (1.04–1.50)	0.016	1.11 (0.92–1.34)	0.27	1.11 (0.92–1.34)	0.29
FGF21 quartile
Quartile 1	1274	185	Reference		Reference		Reference
Quartile 2	1275	213	0.98 (0.63–1.54)	0.95	0.88 (0.55–1.39)	0.57	0.87 (0.55–1.38)	0.55
Quartile 3	1275	229	1.29 (0.85–1.98)	0.23	1.12 (0.72–1.73)	0.63	1.11 (0.71–1.72)	0.65
Quartile 4	1274	259	1.65 (1.10–2.48)	0.015	1.33 (0.86–2.06)	0.19	1.33 (0.86–2.05)	0.20
Overall P-value				0.024		0.24		0.24

For continuous FGF21 levels, data are expressed as HR (95% CI) in terms of per SD (1.36) increase in ln-transformed levels. Quartiles 1, 2, 3 and 4 were defined as FGF21 levels of ≤79.4, 79.5–144.0, 144.1–241.9 and ≥242.0 pg/mL, respectively.

^aAdjusted for age, sex and race/ethnicity.

^bFurther adjusted for BMI, education, smoking, smoking pack-years, diabetes, systolic blood pressure, use of antihypertensive medication acting on RAAS, use of other antihypertensive medication, use of lipid-lowering medication, high-density lipoprotein cholesterol, triglycerides, HOMA2-IR, homocysteine, interleukin-6, C-reactive protein and fibrinogen.

^cFurther adjusted for baseline UACR and eGFR.